OncoDaily IO路 @OncoDailyIO 路 X路路 15 hours agoScore70
Body 路 original
馃К Phase III INTerpath-001: Adjuvant intismeran + pembrolizumab improved RFS vs pembrolizumab + placebo in resected stage IIB鈥揑V melanoma.
24-month RFS: 82.2% vs 70.0%
HR 0.58; P <0.001
DMFS also improved; OS not yet reported.
https://oncodaily.com/oncolibrary/immune-oncology/interpath-001-2
#ESMO2026 #OncoDaily #INTerpath001
5 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: OncoDaily IO 路 x.com